Pilot study of 1650-G: A simplified cellular vaccine for lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 1, 2011, Pages 169-173

  Hirschowitz, Edward A ^a,b   Mullins, Alan ^c   Prajapati, Dattatraya ^c   Baeker, Thomas ^d   Kloecker, Goetz ^e   Foody, Teresa ^a   Damron, Kristine ^f   Love, Celia ^f   Yannelli, John R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Lexington Veteran's Administration Medical Center   (United States)

^c Owensboro Medical Health System   (United States)

^d Commonwealth Cancer Center ^*  (United States)

^e University of Louisville School of Medicine   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Clinical trials; Immunotherapy; Lung cancer; Vaccines

Indexed keywords

1650 G VACCINE; CANCER VACCINE; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; CANCER IMMUNIZATION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; ERYTHEMA; HUMAN; IMMUNE RESPONSE; INJECTION SITE INDURATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 78651092351     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181fb5c22     Document Type: Article

References (17)

1. Hirschowitz EA, Yannelli JR. Immunotherapy for lung cancer. Proc Am Thorac Soc 2009;6:224-232.
2. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-6681.
3. Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multicenter, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25:398s.
4. Brichard VG, Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to phase III clinical development. Vaccine 2007;25s2:B61-B71.
5. Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol 2008;3:735-744.
6. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002;25:97-138.
7. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004;53:275-306.
8. Bolonaki I, Kotsakis A, Papadimitraki E, et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007;25:2727-2734.
9. Carbone DP, Ciernik IF, Kelley MJ, et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 2005;23:5099-5107.
10. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-3094.
11. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24:4721-4730.
12. Barve M, Bender J, Senzer N, et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 2008;26:4418-4425.
13. Dangoor A, Lorigan P, Keilholz U, et al. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother 2010;59:863-873.
14. Hirschowitz EA, Foody T, Kryscio R, et al. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004;22:2808-2815.
15. Hirschowitz EA, Foody T, Hidalgo GE, et al. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007;57:365-372.
16. Hirschowitz EA, Hiestand DM, Yannelli JR. Vaccines for lung cancer. J Thorac Oncol 2006;1:93-104.
17. Keilholz U, Martus P, Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 2006;12: 2346S-2352S.